CurrentmediviewcurativePolicy MM-PNP-026

Diagnosis and Medical Management of Sleep Apnea

Customize your policy alerts

Sign up for mediviewcurative Policy MM-PNP-026 alerts

Get alerted when Policy MM-PNP-026 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines clinical criteria and testing requirements for diagnosing and medically managing obstructive sleep apnea (OSA), including attended in-lab polysomnography and unattended home sleep testing; applies to members of the Curative Health Plan (adults and pediatric references included).

Policy Summary

Payermediviewcurative

PolicyDiagnosis and Medical Management of Sleep Apnea

Policy CodePolicy MM-PNP-026

Change TypeNo material change

Effective DateDec 1, 2023

Next Review Date

Key ActionEnsure documented qualifying sleep study results and required clinical documentation (AHI/RDI thresholds, event counts, and adherence/trial evidence) are included with prior authorization requests.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

AHI >5Diagnosis threshold (symptomatic adults)

AHI ≥15Moderate OSA / split-night criterion

Up to 2x/yearRepeat testing frequency allowed

≥4h/70% nightsCPAP adherence definition

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentmediviewcurativePolicy MM-PNP-026

Diagnosis and Medical Management of Sleep Apnea

Customize your policy alerts

Sign up for mediviewcurative Policy MM-PNP-026 alerts

Get alerted when Policy MM-PNP-026 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payermediviewcurative

PolicyDiagnosis and Medical Management of Sleep Apnea

Policy CodePolicy MM-PNP-026

Change TypeNo material change

Effective DateDec 1, 2023

Next Review Date

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

AHI >5Diagnosis threshold (symptomatic adults)

AHI ≥15Moderate OSA / split-night criterion

Up to 2x/yearRepeat testing frequency allowed

≥4h/70% nightsCPAP adherence definition

5 yearsReplacement RUL for PAP devices

Coverage Criteria — Testing, Devices, Therapies, and Procedures

Attended Full-Channel NPSG

Covered when ANY of the following indications are met (attended in‑lab NPSG Type I):

Indications for attended NPSG: Pediatric patients (<18 years) OR individuals who do not meet criteria for an unattended home sleep apnea test OR a previous home sleep apnea test failed to establish the diagnosis in an individual with high pretest probability OR a previous home sleep apnea test was technically inadequate OR failure of resolution or recurrence of symptoms during treatment OR testing to rule out other sleep disorders (central sleep apnea, injurious parasomnias, narcolepsy) OR presence of comorbidities that might alter ventilation or decrease accuracy of home testing (e.g., moderate–severe pulmonary disease, neuromuscular disease, stroke with respiratory effects, epilepsy, congestive heart failure NYHA III/IV, pulmonary hypertension, chronic opioid use, super obesity) OR lack of mobility/dexterity to use portable monitoring

From attended NPSG section

In‑lab CPAP titration criteria: To initiate and titrate CPAP in adults with AHI or RDI ≥15 events/hour OR AHI or RDI ≥5 events/hour with one or more signs or symptoms associated with OSA (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, stroke). For pediatric patients: AHI/RDI ≥5 OR AHI/RDI ≥1.5 with symptoms (excessive daytime sleepiness, behavioral problems, hyperactivity).AHI/RDI numeric thresholds as stated

Also supports implantation criteria for Inspire System

Required monitoring channels for supervised PSG: A supervised polysomnogram must include at minimum: EEG, EOG, submental (chin) EMG, extremity muscle activity, respiratory effort, airflow, arterial oxygen saturation, and ECG or heart rate.

Minimum elements for supervised polysomnogram

Unattended Home Sleep Apnea Testing

Covered when ALL of the following are met for adult individuals:

Device and channel requirements: Home sleep study uses a Type II, Type III, or Type IV(A) device measuring airflow and at least two other channels, or a device measuring 3+ channels including oximetry, actigraphy and peripheral arterial tone (e.g., WatchPAT). A single unattended test must record a minimum of three channels (nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry) or alternatively PAT, oximetry and actigraphy.minimum 3 channels

Device/channel requirements for home testing

Patient selection criteria: Patient is an adult at moderate or high risk for OSA per policy guidelines AND has no history or exam evidence of conditions that might alter ventilation or require alternative testing/treatment (central sleep apnea, congestive heart failure, chronic pulmonary disease, obesity hypoventilation syndrome, neuromuscular disorders with sleep symptoms, narcolepsy, injurious parasomnias).

Excludes patients with listed comorbidities

Repeat Sleep Studies

Repeat (up to twice yearly) attended or unattended sleep studies are covered for any of the following:

Indications for repeat testing: To assess efficacy of surgery or oral appliance/device therapy OR to re‑evaluate diagnosis and need for continued CPAP after significant weight change or change in symptoms suggesting retitration or discontinuation OR to determine whether PAP settings need change in persons with new or persistent symptoms after interrogation of current PAP device OR to assess response after upper airway surgery or oral appliance treatment.up to 2 per year

Repeat testing frequency and circumstances

Replacement equipment exception: Repeat sleep testing for persons getting replacement CPAP equipment is not medically necessary unless one of the listed indications for repeat testing is present.

Exception for replacement equipment

Not Medically Necessary Devices

Explicitly not medically necessary:

Insufficient‑channel/invalid devices: Devices that do not provide measurement of apnea‑hypopnea index (AHI) and arterial oxygen saturation (examples: Biancamed SleepMinder, SNAP testing with fewer than three channels, SleepImage Sleep Quality Screener; note ApneaLink without airflow does not meet Type IV criteria). Such devices are considered not medically necessary.

Examples provided in policy

Coverage for CPAP/APAP/BiPAP

Covered when the following diagnostic criteria from a qualifying sleep study are met:

Primary numeric thresholds: Either AHI or RDI ≥15 events/hour with a minimum of 30 events; OR AHI or RDI ≥5 and <15 events/hour with a minimum of 10 events AND at least one qualifying condition (documented history of stroke, documented hypertension, documented ischemic heart disease, documented symptoms of impaired cognition/mood/insomnia, excessive daytime sleepiness (Epworth>10), >20 desaturations <85% during full night, or any desaturation <70%).see text

AHI reported only in Type I/II; RDI reported in Type III/IV/home

Oral appliance coverage

Covered when ALL of the following are met:

Oral appliance conditions: Diagnosis of clinically significant OSA meeting testing/provider criteria; AHI/RDI/REI ≥15 with minimum 30 events OR AHI/RDI/REI ≥5 and <15 with minimum 10 events plus documented qualifying comorbidity or symptom; and one or more of: patient is not a candidate for CPAP, CPAP ineffective despite a 45‑day trial with participation in a CPAP compliance program, noncompliant after a 45‑day CPAP trial with compliance program, or patient preference to use an oral appliance as initial therapy; device prescribed by physician, custom‑fabricated and fit by qualified dental personnel, and absence of TMJ dysfunction or periodontal disease. Replacement at 5‑year RUL as noted.

Oral appliance documentation requirements included

Coverage for BiPAP/alternatives

Covered when ALL of the following are met:

BiPAP/alternative PAP criteria: Member is intolerant of CPAP or CPAP is ineffective despite optimal therapy; medical records document proper interface fitting and that CPAP/AutoPAP pressure settings were tried and failed and that lower pressure settings were attempted but did not adequately control symptoms, improve sleep quality, or reduce AHI/RDI.

Defines ineffective/intolerance and documentation required

Attended NPSG and repeat testing

Attended in‑lab NPSG is medically necessary for persons with OSA who meet indications for attended testing; repeat sleep studies may be performed up to twice a year for listed indications.

Indications for attended NPSG titration/monitoring: Titrate CPAP when split‑night insufficient (AHI <15 in first two hours) or when split‑night did not abolish the majority of events; monitor CPAP when persistent symptoms despite documented AHI <5 on CPAP and documented compliance (CPAP used ≥4 hours/night on ≥70% of nights for two or more months); confirm diagnosis prior to upper airway surgery; video‑EEG‑NPSG for suspected seizure‑related arousals.

Split‑night guidance and monitoring criteria

Hypoglossal nerve stimulation (UAS/Inspire)

Covered when ALL of the following are met:

UAS candidate criteria: Age ≥18 years; BMI <40 kg/m2; PSG performed within 24 months of first consultation for implant; predominantly obstructive events (central and mixed apneas <25% of total AHI); AHI 15–100 events/hour; a minimum of one month of CPAP monitoring documenting CPAP failure (AHI >15 despite CPAP usage) or CPAP intolerance (<4 hours/night on ≥5 nights/week); absence of complete concentric collapse at the soft palate on DISE; no other anatomical findings that would compromise device performance (e.g., tonsil size 3 or 4).See individual node texts

FDA‑approved systems only; non‑FDA systems considered experimental

Surgical procedures

Selected surgeries and procedures considered medically necessary when clinically indicated:

Medically necessary surgeries list: Adult lingual or pharyngeal tonsillectomy and adenoidectomy when hypertrophied tonsils or adenoid hyperplasia compromise airway; DISE medically necessary for evaluation prior to FDA‑approved hypoglossal nerve stimulation but experimental for other indications; jaw realignment surgery may be medically necessary for persons who fail other treatments (may be subject to specialty review).

See surgical procedures section

Hypoglossal Nerve Neurostimulation (FDA-approved systems)

Covered when ALL of the following are met:

Hypoglossal neurostimulation (FDA‑approved) criteria: Member is 18 years of age or older; BMI <40 kg/m2; PSG performed within 24 months of first consultation; predominantly obstructive events (central and mixed apneas <25% of total AHI); AHI 15–100 events/hour; minimum one month of CPAP monitoring documenting CPAP failure (AHI >15 despite CPAP) or CPAP intolerance (<4 hours/night on ≥5 nights/week); absence of complete concentric collapse at the soft palate on DISE; no other anatomical findings that would compromise device performance (e.g., tonsil size 3 or 4).AHI 15–100; BMI <40; age ≥18

Non‑FDA systems considered experimental/investigational

Jaw Realignment Surgery

Covered when ALL of the following are met:

Jaw realignment surgery: Member has failed other treatment approaches for OSA; case may be subject to review by Oral and Maxillofacial Surgery Unit because of extent of surgery. Orthodontic therapy (placement of brackets/wires) is excluded from standard medical coverage.N/A

Specialty review may be required

Nasal Surgery

Covered when ALL of the following are met:

Nasal surgery: Nasal valve surgery, polypectomy, septoplasty, and turbinectomy are medically necessary for adults with nasal obstruction and CPAP intolerance related to nasal issues and high pressure requirements; turbinectomy for severe obstruction from hypertrophied inferior turbinates; polypectomy for severe obstruction from nasal polyps. Nasal valve surgery requires photos documenting valve collapse.N/A

Documentation requirements noted

Palatopharyngoplasty

Covered when ALL of the following are met:

Palatopharyngoplasty (e.g., UPPP and related procedures) is medically necessary for OSA members who meet CPAP/AutoPAP criteria but have inadequate response or are intolerant to CPAP/AutoPAP despite adjustments to pressure and mask; medical records must document attempted CPAP/AutoPAP prior to surgery. Considered experimental for non‑obstructive indications (UARS, etc.).N/A

CPAP trial must be documented

Other surgical procedures considered medically necessary

Covered when clinically indicated:

Other surgical procedures: Tongue base reduction procedures (midline glossectomy, lingualplasty) are medically necessary to relieve lower pharyngeal airway obstruction; tonsillectomy is medically necessary with UPPP in members who meet UPPP criteria.N/A

Experimental, investigational, or not medically necessary diagnostics and treatments

The following are considered experimental, investigational, or not medically necessary:

Diagnostics - experimental/investigational: Acoustic pharyngometry; actigraphy when used alone; daytime nap polysomnography; diagnostic audio recording with/without oximetry; dynamic sleep MRI; various biomarkers and genetic studies; and other listed diagnostic techniques are considered experimental or investigational for diagnosing OSA.N/A

See diagnostic procedures list

Treatments - experimental/investigational (medical): Daytime tongue stimulation (e.g., eXciteOSA), BiPAP with backup rate (adaptive servoventilation), oral appliances for UARS or non‑OSA indications, Winx Therapy/oral pressure therapy, and other listed devices/therapies are considered experimental or investigational.N/A

See treatment list

Treatments - experimental/investigational (surgical):

Experimental & Investigational - Surgical/Device

Curative considers the following surgeries and procedures experimental and investigational for treatment of OSA:

Experimental/Investigational Procedures List: Includes apnea‑triggered muscle stimulation; cardiac (atrial) pacing; CAPSO; contraction of the sternothyroid muscle with ansa cervicalis stimulation; positional therapy devices (e.g., Lunoa); EASE; epiglottidectomy/partial epiglottidectomy; genioplasty and genial tubercle advancement; injection snoreplasty; mandibular distraction osteogenesis; nasal dilators; nasal EPAP (e.g., Provent, ULTepap); NighLase laser therapy; Pillar Palatal Implant System; rapid maxillary expansion; remotely controlled mandibular positioner as predictive screening tool; respiratory muscle therapy; somnoplasty and coblation; surgical palatal expansion; the Advance System; AIRvance (Repose) and Encore tongue base suspension; Winx Therapy System; TENS; uvulectomy and LAUP.

Full list in policy chunks 54–55

Uvulectomy/LAUP — exception by individual case review

Uvulectomy/LAUP general stance and limited exception:

Uvulectomy/LAUP: Cold knife uvulectomy and laser assisted uvuloplasty (LAUP) are considered experimental and investigational for OSA because they are not as effective as UPPP. However, Curative may consider these procedures medically necessary upon individual case review for members with severe OSA who are unable to undergo UPPP and have failed a trial of CPAP/AutoPAP or an oral appliance/device. Note: uvulectomy is considered medically necessary for uvular neoplasm and emergent acute uvular edema causing respiratory distress; experimental for recurrent throat infections and other indications.

Exception pathway via individual case review

Sleep study devices that do not provide measurements of both the apnea‑hypopnea index (AHI) and oxygen saturation are considered not medically necessary because they do not supply sufficient information to prescribe therapy. Examples called out by policy include the Biancamed SleepMinder, SNAP testing with fewer than three channels, and the SleepImage Sleep Quality Screener. (Note: devices that meet channel and signal requirements—e.g., ApneaLink Plus with airflow and five channels—may meet device criteria.)

Treatment aimed at snoring alone without clinically significant OSA is considered not medically necessary. Similarly, oral appliances marketed or intended solely for snoring (for example, specific snoring-only appliances referenced in policy) are not covered as medically necessary therapy. Coverage for mandibular advancement oral appliances is limited to members who meet the policy's diagnostic criteria for obstructive sleep apnea (see oral appliance criteria).

Drug‑induced sleep endoscopy (DISE) is considered medically necessary only when performed to evaluate candidacy for FDA‑approved hypoglossal nerve stimulation (UAS/Inspire) where multiple levels of obstruction are suspected and all UAS criteria are otherwise met. DISE is considered experimental and investigational for all other indications.

Hypoglossal nerve neurostimulation systems that are not FDA‑approved (for example, Apnex HGNS™, aura6000™, ImThera, WellStar implants) are considered experimental and investigational for treatment of adult OSA and are not covered under this policy.

Orthodontic therapy (the placement of orthodontic brackets and wires) is excluded from coverage under standard Curative medical plans regardless of whether it is performed in conjunction with OSA surgery or to support jaw realignment procedures. Members should consult their dental benefits for coverage of orthodontic services.

The Zzoma positional device is considered not medically necessary because the policy finds insufficient evidence that it is superior to other interventions for maintaining a non‑supine sleeping position.

Over‑the‑counter bite guards are not covered under this medical policy and are considered outside the scope of medically necessary treatment for OSA or related conditions.

Uvulectomy (cold‑knife or laser assisted uvuloplasty/LAUP) is generally considered experimental and investigational for treatment of OSA because it has not demonstrated effectiveness comparable to UPPP. However, uvulectomy is medically necessary for removal of a uvular neoplasm and may be considered medically necessary as an emergent procedure for acute uvular edema causing acute respiratory compromise. Curative may also consider uvulectomy or LAUP medically necessary on individual case review for selected members with severe OSA who cannot undergo UPPP and have failed conservative therapies.

Devices that fail to provide explicit measurements of AHI and oxygen saturation are considered not medically necessary for diagnostic use because they do not deliver the essential physiologic data required to establish or quantify OSA and to guide treatment decisions. Examples and rationale for exclusion are provided in the policy's home sleep testing section.

Repeat sleep testing for members obtaining replacement CPAP equipment is not medically necessary unless one of the policy's specified indications for repeat testing is present (e.g., to reassess efficacy after surgery or oral appliance therapy, to re‑evaluate need for CPAP following substantial weight change or other clinical change, or to determine need to change PAP settings for new or persistent symptoms). The policy allows up to two sleep studies per year when clinically indicated.

Certain PAP accessories are classified as convenience items and are not medically necessary for coverage. Examples listed in the policy include PAP bed pillows, batteries for PAP devices, and DC adapters. Standard medically necessary PAP supplies (masks, tubing, filters, humidifiers, replacement cushions, etc.) remain covered per policy and Medicare DME MAC quantity rules.

Diagnostic sleep testing is not medically necessary for conditions that can be diagnosed by other means or when the test type is inappropriate. The policy lists examples including bruxism, insomnia, restless leg syndrome, snoring without other signs/symptoms of OSA, and several other non‑OSA conditions. Additionally, unattended (unsupervised) sleep studies are investigational in low‑risk individuals and in children, and use of devices lacking required channels or signals may be excluded.

Continuous positive airway pressure (CPAP) devices and related coverage are contingent on meeting the policy's diagnostic and clinical criteria. If the qualifying sleep study results and clinical requirements are not met, CPAP is not covered. Consistent with the policy, treatment of snoring without significant OSA is not medically necessary and does not qualify a member for CPAP or other covered OSA therapies.

A broad list of procedures and devices is designated as experimental, investigational, or not medically necessary for the treatment of OSA due to insufficient evidence of safety or effectiveness. Items specifically enumerated include a range of surgical techniques (e.g., AIRvance/Repose and Encore tongue base suspension, Pillar palatal implants, somnoplasty/coblation, many others) and several device‑based therapies (e.g., nasal EPAP, Winx oral pressure therapy). Requests for these listed interventions are subject to denial under this policy.

Coding, Thresholds, and Index Definitions

Sleep study types referenced (no billable codes listed in excerpt)mixed

Type I	Attended full-channel nocturnal polysomnography (NPSG) performed in a healthcare facility
Type II	Unattended/home sleep study with sleep time measurement allowing AHI reporting
Type III	Unattended/home sleep study reporting RDI (respiratory disturbance index)
Type IV	Unattended/home sleep study reporting RDI or fewer channels (home studies)
SNAP testing (≥3 channels)	SNAP home testing using 3 or more channels considered medically necessary
SNAP testing (<3 channels)	SNAP testing using less than 3 channels considered experimental and investigational
Video-EEG-NPSG	NPSG with video monitoring and extended EEG channels for suspected seizure-related arousals

AHI severity thresholds

Mild OSA diagnostic thresholdAHI >5 events/hour in an adult with symptoms (e.g., excessive daytime sleepiness or unexplained hypertension)

Moderate OSA thresholdAHI ≥15 events/hour

Severe OSA thresholdAHI >30 events/hour

AHI/RDI thresholds and event counts

Primary numeric qualifying criteriaAHI or RDI ≥15 events/hour with a minimum of 30 events

Alternate qualifying criteriaAHI or RDI ≥5 and <15 events/hour with a minimum of 10 events plus at least one qualifying comorbidity or symptom (e.g., stroke, hypertension, ischemic heart disease, impaired cognition/mood/insomnia, excessive daytime sleepiness with Epworth >10, >20 desaturations <85% during full night, or any desaturation <70%)

Provider Steps, Documentation, Prior Authorization, and Review

Prior Authorization

Medical necessity required for testing

Attended in‑lab polysomnography (Type I) and unattended home sleep apnea tests (Types II–IV) are considered medically necessary only when the member meets the policy’s specified clinical indications and device/channel requirements; ensure documentation supports the indicated test type and reason for testing.

Prior Authorization

PA: submit qualifying sleep study + clinical criteria

Prior authorization for CPAP/APAP and oral appliances requires submission of qualifying sleep study results that meet AHI/RDI thresholds and minimum event counts, plus supporting clinical documentation of symptoms or comorbidities per policy criteria.

AHI/RDI ≥15 events/hour with a minimum of 30 events; OR
AHI/RDI ≥5 and <15 with a minimum of 10 events plus a documented qualifying condition (e.g., stroke, hypertension, ischemic heart disease, impaired cognition/mood/insomnia, Epworth >10, or significant desaturations).

Background and Rationale

Polysomnography (attended, in‑lab) with EEG, EOG, and submental EMG is the criterion standard for diagnosing sleep apnea because it enables sleep staging and accurate event scoring. Attended full‑channel nocturnal polysomnography includes respiratory channels, oximetry, and cardiac monitoring and is required for patients who do not meet criteria for unattended home testing, when comorbidities may alter ventilation, or when other sleep disorders must be evaluated.

Definitions and Key Terms

Polysomnogram (PSG)

Required PSG channels for stagingEEG, submental EMG, and electro-oculogram (EOG) are required for sleep staging in attended polysomnography

Additional PSG parametersRespiratory airflow and effort, oxygen desaturation, ECG, sleep position, leg movement, chest and abdominal excursions may also be included as clinically indicated

Split-night capabilityAttended PSG can be performed as a split-night study to allow diagnosis and in-lab CPAP titration during the same night when appropriate

Apnea-Hypopnea Index (AHI)

AHI definitionTotal number of apneas and hypopneas per hour of sleep; used to grade OSA severity and guide management

Reporting contextAHI reported only in Type I or Type II studies; when sleep onset/offset unknown use RDI

Policy Revision History

2023-12-01policy_effectiveLatest

Original effective date of the policy (MM-PNP-026) established.

Policy Summary

Payermediviewcurative

PolicyDiagnosis and Medical Management of Sleep Apnea

Policy CodePolicy MM-PNP-026

Change TypeNo material change

Effective DateDec 1, 2023

Next Review Date

SourceLink

On This Page

A broad list of surgical procedures (e.g., apnea‑triggered muscle stimulation; CAPSO; genioplasty; mandibular distraction osteogenesis; nasal EPAP systems like Provent; Pillar Palatal Implant; somnoplasty and coblation; AIRvance/Repose and Encore tongue base suspension; Winx Therapy; uvulectomy/LAUP except in specified exceptions; and others) are considered experimental and investigational for OSA.

See surgical experimental list

Minimum sleep study recording requirementSleep study based on a minimum of 2 hours of continuous recorded sleep, or shorter periods only if the number of recorded events meets the event minimums for the corresponding threshold

PAP adherence threshold

Standard adherence definition for continued coverageUse ≥4 hours/night on ≥70% of nights during a consecutive 30-day period (documented anytime during initial usage)

Alternate adherence metric noted elsewherePolicy indicates in some contexts an average of 4.5 hours/night may be required to demonstrate failure before alternatives are considered

Documentation requirementTreating physician must review objective evidence of adherence when documenting clinical benefit for continued medical necessity

Apnea-hypopnea index (AHI)

UAS AHI range requirementAHI 15 to 100 events per hour

Reporting contextAHI reported only in Type I or Type II studies; RDI used for Type III/IV/home studies

RelevanceAHI range is an eligibility criterion for FDA-approved hypoglossal nerve neurostimulation (UAS)

Body mass index (BMI)

UAS BMI cutoffBody mass index (BMI) <40 kg/m2

Use for eligibilityBMI threshold applied as part of candidate selection for FDA-approved hypoglossal nerve neurostimulation

Measurement contextBMI must be documented in clinical record prior to implant

Age

Minimum age for UAS18 years or older

Adult-only interventionPolicy restricts hypoglossal nerve neurostimulation to adult members

DocumentationAge must be verifiable in medical record and consultation note

Central/Mixed apneas proportion

Central/mixed apneas proportion limitCentral and mixed apneas must constitute less than 25% of the total AHI

Definition relevanceRequirement ensures predominantly obstructive events for UAS candidacy

Assessment methodProportion determined from PSG data reported in the diagnostic study

CPAP usage for intolerance definition

Definition of CPAP intolerance for UAS pathwayCPAP intolerance: <4 hours/night on ≥5 nights/week documented during at least one month of monitoring

CPAP failure distinctionCPAP failure defined separately as AHI >15 despite CPAP usage (documented during at least one month of monitoring)

Documentation requirementOne month of CPAP monitoring documentation is required to demonstrate failure or intolerance prior to UAS consideration

CPAP minimum trial

Minimum CPAP rental trial before purchase3 months (rental with fees applied to purchase price)

Purpose of trialTo document patient compliance, tolerance, and clinical benefit prior to purchase

Inclusion of accessoriesPayment for CPAP includes necessary accessories; separate charges for mask, tubing, cannula, or maintenance services are not covered during rental period

Prior Authorization

Specialty review may be required for jaw realignment

Jaw realignment (mandibular osteotomy, genioglossal advancement, hyoid procedures) may require review by Curative’s Oral and Maxillofacial Surgery Unit; route cases for specialty review when surgery extent warrants evaluation of medical necessity.

Prior Authorization

Tracheostomy requires medical review and justification

Requests for tracheostomy for OSA must be submitted for medical review and include documentation that other interventions were insufficient; tracheostomy supplies and quantities will follow Medicare DME MAC rules.

Billing Rule

CPAP rental-to-purchase trial: document 3‑month trial

CPAP equipment is provided initially as a rental; document a minimum three‑month rental trial demonstrating compliance, tolerance, and clinical benefit prior to purchase (rental fees apply toward purchase).

Minimum rental trial period: 3 months.
Rental fees are applied to purchase price if purchased after trial.

Step Therapy

Split‑night study guidance for titration

A split‑night in‑lab study can substitute for a separate titration when diagnostic AHI is sufficiently high early in the study; perform a split‑night titration when AHI >15 in the first 2 hours (otherwise a separate full-night titration may be required).

Split‑night titration indicated when AHI >15 in first 2 hours of diagnostic study.
If AHI ≤15 in first 2 hours or split‑night does not abolish the majority of events, an additional full‑night CPAP titration is medically necessary.

Step Therapy

Therapy sequencing — CPAP first; document acclimation/failure

Sequence therapy with CPAP as first‑line; oral appliances or alternative PAP (BiPAP/DPAP/VPAP) may be considered only after documented CPAP trials/acclimation efforts showing intolerance or ineffectiveness.

CPAP is first‑line therapy.
Document acclimation efforts (mask fitting, alternate masks, humidification, ramping, emotional support) and at least two months of attempts when indicated.
Prior to alternative PAP or oral appliance coverage, show documented CPAP failure or intolerance per policy thresholds and compliance program participation (e.g., 45‑day trial for oral appliance pathway where specified).

Prior Authorization

Conservative therapy prerequisites before surgery

Before elective surgical interventions (hypoglossal nerve stimulation, palatopharyngoplasty, jaw realignment, tongue base reduction), document that conservative therapies (CPAP/AutoPAP and other less invasive options) were tried and failed or were not tolerated as required by the specific surgical criteria.

For UAS: at least one month of CPAP monitoring documenting CPAP failure (AHI >15 despite usage) or CPAP intolerance (<4 hours/night on ≥5 nights/week).
Palatopharyngoplasty and other surgical records must document attempted CPAP/AutoPAP before surgery.

Denial Risk

Requests for listed experimental procedures/devices — expect denial/exception review

For procedures or devices listed as experimental/investigational, route requests per policy—these items are generally subject to denial unless an individual case review exception is documented (e.g., uvulectomy exception pathway).

Many listed surgeries/devices (AIRvance/Repose, Pillar implants, nasal EPAP, Winx, somnoplasty, coblation, uvulectomy/LAUP, etc.) are considered experimental/investigational and subject to denial.
Curative may consider uvulectomy/LAUP medically necessary only upon individual case review for severe OSA patients who cannot undergo UPPP and have failed CPAP/AutoPAP and oral appliance/device therapy.

Documentation Required

Document interpreter credentials for unattended testing

Physician interpretation of unattended sleep apnea testing must be documented and accompanied by verification of qualifying credentials (ABSM certification, ABMS subspecialty certification, completion of training pending exam, or active staff membership at an accredited sleep center).

Acceptable documentation: current ABSM certification; ABMS sleep subspecialty certification; completed training pending examination; or active staff membership at an AASM or Joint Commission‑accredited sleep center.

Documentation Required

Continued therapy: document clinical benefit + adherence

For continued PAP coverage, the treating physician must document a face‑to‑face clinical reevaluation showing symptom improvement and objective adherence evidence defined as ≥4 hours/night on ≥70% of nights during a consecutive 30‑day period.

Face‑to‑face clinical reevaluation documenting symptom improvement.
Objective adherence: ≥4 hours/night on at least 70% of nights during any consecutive 30‑day period.

Documentation Required

Document CPAP failure/intolerance with mask fit, titration, and acclimation records

When claiming CPAP failure or intolerance to justify alternatives, document proper mask/interface fitting, trials of appropriate CPAP/AutoPAP pressure settings, titration efforts, acclimation measures, and device adherence and troubleshooting attempts.

Document proper interface fitting and that lower pressure settings were tried and failed to control symptoms or reduce AHI/RDI.
Document acclimation efforts (mask alternatives, humidification, ramping, emotional support) and any dedicated in‑lab retitration or home acclimation trials with follow‑up.

Billing Rule

Document 3‑month CPAP rental trial before purchase

Document a minimum three‑month CPAP rental trial (with compliance/tolerance and clinical benefit) prior to purchase; rental fees are applied to the purchase price.

Minimum documented rental period: 3 months.
Evidence of compliance, tolerance, and clinical benefit required before purchase.

Documentation Required

Split‑night study documentation and when separate titration is required

Ensure split‑night study documentation explicitly reports the early diagnostic AHI and whether CPAP titration during the latter portion abolished the majority of obstructive events; if not, document need for separate full‑night titration.

Report diagnostic AHI in first 2 hours and result of titration portion.
If AHI ≤15 in first 2 hours or titration inadequate, submit documentation supporting separate titration study.

Documentation Required

Therapy sequencing, acclimation, and oral appliance documentation requirements

Before authorizing alternatives (oral appliances, BiPAP) or surgery, document attempts at therapy sequencing and acclimation: minimum acclimation period when indicated, CPAP compliance program participation, and objective usage data; for oral appliances include prescription and custom fabrication details.

Acclimation efforts should be attempted for a minimum of two months with documentation and compliance chip information before declaring CPAP failure.
Oral appliance requests must include physician prescription, custom fabrication and fitting by qualified dental personnel, and absence of TMJ or periodontal disease.
For oral appliance coverage pathways, document CPAP trials (45 days) and compliance program participation when required.

Prior Authorization

Document conservative therapy trials and outcomes before surgery

Document conservative therapy prerequisites prior to surgical options: evidence of CPAP/AutoPAP trials (including monitoring data), documented acclimation efforts, and failure or intolerance per policy definitions.

CPAP failure: AHI >15 despite CPAP usage documented during at least one month of monitoring.
CPAP intolerance: <4 hours/night on ≥5 nights/week documented during at least one month of monitoring.
Surgical candidates (e.g., palatopharyngoplasty) must have medical records documenting attempted CPAP/AutoPAP.

Denial Risk

Denial risk: insufficient‑channel devices and invalid indices

Do not submit sleep study results derived from devices that lack measurement of AHI and oxygen saturation for device or treatment authorization; such studies are considered not medically necessary and risk denial.

Examples of excluded devices: SleepMinder, SNAP testing with fewer than three channels, SleepImage Sleep Quality Screener.
ApneaLink without airflow does not meet Type IV criteria; ApneaLink Plus (5 channels including airflow) may meet criteria.

Denial Risk

Denial triggers: missing UAS eligibility documentation

Requests for UAS (hypoglossal nerve neurostimulation) will be denied if the submission does not document required eligibility criteria (age, BMI, PSG within 24 months, AHI 15–100, predominance of obstructive events, CPAP trial documentation, and DISE showing absence of complete concentric collapse).

Required documentation: PSG within 24 months, CPAP monitoring (≥1 month) showing failure or intolerance, DISE without complete concentric collapse, AHI 15–100, central/mixed apneas <25% of total AHI, age ≥18, BMI <40 kg/m2.

Clinical roleAHI thresholds are used to determine diagnosis and treatment eligibility

Apnea

Apnea definitionCessation of airflow for at least 10 seconds

ContextUsed in scoring AHI and RDI for sleep studies

Measurement noteApnea identification requires adequate respiratory airflow monitoring in the study channels

Hypopnea

Hypopnea definitionAn abnormal respiratory event ≥10 seconds with ≥30% reduction in thoraco-abdominal movement or airflow and ≥4% oxygen desaturation

Scoring implicationsHypopneas contribute to AHI/RDI event counts used for diagnosis and coverage decisions

Minimum durationEvent duration threshold is at least 10 seconds

AHI (reporting note)

AHI reporting limitationAHI is the average number of apneas and hypopneas per hour of sleep and is reported only in Type I or Type II studies where sleep time is measured

Use in policyAHI values are applied to classify OSA severity and treatment eligibility

Alternative indexWhen sleep time cannot be measured, RDI should be used instead for Type III/IV/home studies

RDI

RDI definitionEpisodes of apnea and hypopnea per hour of recording (reported in Type III, Type IV, and home studies)

ContextRDI used when sleep onset/offset are unknown and for home sleep testing modalities

EquivalencePolicy uses AHI or RDI thresholds interchangeably depending on study type for coverage determinations

CPAP failure

CPAP failure definitionAHI greater than 15 despite CPAP usage documented during at least one month of CPAP monitoring

Role in advanced therapyRequired documentation to consider alternatives such as hypoglossal nerve neurostimulation

Monitoring durationAt least one month of CPAP monitoring is required to establish failure

CPAP intolerance

CPAP intolerance definitionCPAP use less than 4 hours per night on at least 5 nights per week documented during at least one month of monitoring

Documentation requiredRecords must also document mask fitting and attempts at pressure adjustment or acclimation as part of intolerance claim

Distinction from failureIntolerance is separate from CPAP failure (residual AHI >15 despite use)

Predominantly obstructive events

Predominantly obstructive events criterionCentral and mixed apneas must constitute less than 25% of the total AHI to be considered predominantly obstructive

ApplicationRequired for hypoglossal nerve neurostimulation candidacy

Source of determinationDerived from PSG diagnostic data

Tongue base suspension (AIRvance/Repose, Encore)

Tongue base suspension descriptionMinimally invasive procedures intended to stabilize the tongue base to treat sleep disordered breathing; preliminary studies show inconsistent success and larger controlled long-term studies are necessary

Policy stanceAIRvance/Repose and Encore tongue base suspension are considered experimental and investigational for OSA

Evidence noteExisting studies report subjective snoring improvement and variable decreases in mean RDI but lack consistent long-term outcomes